VEGFA, AKT1, and IL-6 were recognized as core targets in the network pharmacology prediction study of Astragalus membranaceus in treating the diabetic retinopathy, and the PI3K-Akt signaling pathway role has also been highlighted [33]. This evidence concerns the gene AKT1 and diabetic retinopathy.